Publications
Detailed Information
Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa (R), ZD1839) in chemotherapy-resistant non-small cell lung cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Han, Sae-Won | - |
dc.contributor.author | Hwang, Pil Gyu | - |
dc.contributor.author | Chung, Doo Hyun | - |
dc.contributor.author | Kim, Dong-Wan | - |
dc.contributor.author | Im, Seock-Ah | - |
dc.contributor.author | Kim, Young Tae | - |
dc.contributor.author | Kim, Tae-You | - |
dc.contributor.author | Heo, Dae Seog | - |
dc.contributor.author | Bang, Yung-Jue | - |
dc.contributor.author | Kim, Noe Kyeong | - |
dc.date.accessioned | 2009-11-18T02:28:15Z | - |
dc.date.available | 2009-11-18T02:28:15Z | - |
dc.date.created | 2020-04-08 | - |
dc.date.created | 2020-04-08 | - |
dc.date.created | 2020-04-08 | - |
dc.date.created | 2020-04-08 | - |
dc.date.issued | 2005-01 | - |
dc.identifier.citation | International Journal of Cancer, Vol.113 No.1, pp.109-115 | - |
dc.identifier.issn | 0020-7136 | - |
dc.identifier.other | 95322 | - |
dc.identifier.uri | https://hdl.handle.net/10371/12747 | - |
dc.description.abstract | Gefitinib has shown meaningful antitumor activity with tolerable toxicity in chemotherapy-refractory NSCLC in previous studies. Moreover, EGFR expression failed to show a correlation with response. In an attempt to identify predictive markers of response, we have investigated the tumoral expression of key signaling molecules of EGFR (EGFR, p-EGFR, p-Akt, p-Erk, p-STAT3) by immunohistochemistry and analyzed their correlations with response. Of 65 patients who received gefitinib (250 mg/day) for chemotherapy-refractory NSCLC, there were 14 partial responses (21.5%), 21 stable diseases (32.3%) and 21 progressive diseases (32.3%). Median durations of overall survival and time to progression were 6.7 months and 2.8 months, respectively. Immunohistochemistry was performed in 34 patients with evaluable tissue specimens. EGFR was overexpressed (2+ or 3+) in 32.4% and p-EGFR was positive in 26.5%. The expressions of p-Akt, p-Erk and p-STAT3 were positive(1+ or 2+) in 50%, 38.2% and 79.4%, respectively. The EGFR expression was not correlated with p-EGFR or the downstream molecules. EGFR or p-EGFR status did not correlate with response. Positive expression of p-Erk was significantly associated with poor response (38.1% in -, 14.3% in 1+, 0% in 2+; p = 0.046). Furthermore, tumors with positive p-Akt and negative p-Erk nuclear expression exhibited the best response (60%), whereas there was no response in the opposite [p-Akt (-), p-Erk (+)] cases. Intense nuclear staining of p-Akt (2+) was associated with prolonged TTP (HR 0.25, 95% confidence interval [CI] 0.08-0.79,p = 0.018) and OS (HR 0.16, 95% CI 0.04-0.62, p = 0.008). These results support the assumption that gefitinib responsiveness might be predicted by activated EGFR downstream molecules such as p-Akt and p-Erk. (C) 2004 Wiley-Liss, Inc. | - |
dc.language | 영어 | - |
dc.language.iso | en | en |
dc.publisher | John Wiley & Sons Inc. | - |
dc.title | Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa (R), ZD1839) in chemotherapy-resistant non-small cell lung cancer | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 임석아 | - |
dc.identifier.doi | 10.1002/ijc.20550 | - |
dc.citation.journaltitle | International Journal of Cancer | - |
dc.identifier.wosid | 000225116600015 | - |
dc.identifier.scopusid | 2-s2.0-8644234228 | - |
dc.citation.endpage | 115 | - |
dc.citation.number | 1 | - |
dc.citation.startpage | 109 | - |
dc.citation.volume | 113 | - |
dc.identifier.sci | 000225116600015 | - |
dc.description.isOpenAccess | N | - |
dc.contributor.affiliatedAuthor | Chung, Doo Hyun | - |
dc.contributor.affiliatedAuthor | Kim, Dong-Wan | - |
dc.contributor.affiliatedAuthor | Im, Seock-Ah | - |
dc.contributor.affiliatedAuthor | Kim, Young Tae | - |
dc.contributor.affiliatedAuthor | Kim, Tae-You | - |
dc.contributor.affiliatedAuthor | Heo, Dae Seog | - |
dc.contributor.affiliatedAuthor | Bang, Yung-Jue | - |
dc.contributor.affiliatedAuthor | Kim, Noe Kyeong | - |
dc.type.docType | Article; Proceedings Paper | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | KINASE INHIBITOR ZD1839 | - |
dc.subject.keywordPlus | PHASE-II TRIAL | - |
dc.subject.keywordPlus | TYROSINE KINASE | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordPlus | PATHWAY | - |
dc.subject.keywordPlus | SENSITIVITY | - |
dc.subject.keywordPlus | COMBINATION | - |
dc.subject.keywordPlus | CARCINOMA | - |
dc.subject.keywordPlus | APOPTOSIS | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordAuthor | NSCLC | - |
dc.subject.keywordAuthor | getitimb | - |
dc.subject.keywordAuthor | EGFR | - |
dc.subject.keywordAuthor | p-Akt | - |
dc.subject.keywordAuthor | p-Erk | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.